From BIO Boston: Eamonn Hobbs, CEO of Syncromune

Eamonn Hobbs is a biotech veteran and serial CEO — and in this episode, he shares how Syncromune is rewriting the playbook for immunotherapy.

We talk about:
– How Syncromune’s SYNC-T platform delivered 87% ORR and 53% CR in mCRPC– What it means to synchronize drug, device, and immune response– Raising one of the few $100M Series A rounds in 2024– The mindset needed to build and win in today’s brutal market

Eamonn’s clarity, experience, and grit shine through — this is a must-listen for anyone building in biotech.

More BIO Boston episodes dropping soon.